An Exploratory Open-Label, Non-Randomised, Single Centre Methodology Study to Compare Dynamic Contrast Enhanced CT & MRI as Markers of Changes in Vascular Activity Mediated by a Positive Control Agent (Cediranib), a Potent Inhibitor of VEGF-Driven Angiogenesis in Patients with Advanced Solid Tumours

Christina Messiou¹, Matthew Orton¹, David J. Collins¹, Veronica a Morgan¹, Dorothy Mears², Isabel Castellano², Dionysis Papadatospastos³, Andre Brunetto³, Jooern Ang³, Helen Mann⁴, Jean Tessier⁴, Helen Young⁴, Stan Kaye³, Johann de Bono³, Martin O. Leach¹, Nandita M. deSouza¹

The aim of this study was to establish within patient variability of DCE-MRI vs. DCE-CT in the same patients and compare their ability to measure changes in tumour blood flow and permeability in these patients when treated with the VEGFR tyrosine kinase inhibitor cediranib. Image parameters were reproducible-most were in the range 15-25%. The most reproducible parameter was DCE-MRI EF followed by DCE-MRI Ktrans and iAUC60, and DCE-CT PEI. DCE-MRI and DCE-CT were comparable when assessing changes from baseline in vascular physiology. There was generally a higher percentage change from baseline for parameters measuring area under the curve (iAUC60, PEI).